宫颈癌后装近距离治疗:GO、IPSA与HIPO优化算法对比研究
石翔翔 , 李磊 , 张静 , 庞皓文
西南医科大学学报 ›› 2025, Vol. 48 ›› Issue (04) : 421 -425.
宫颈癌后装近距离治疗:GO、IPSA与HIPO优化算法对比研究
A Comparative Study of GO, IPSA, and HIPO Optimization Algorithms in Cervical Cancer Brachytherapy
目的 探讨宫颈癌后装近距离治疗中正向图形优化算法(graphical optimization, GO)、模拟退火逆向计划优化算法(inverse planning simulated annealing, IPSA)以及混合逆向计划优化算法(hybrid inverse planning optimization, HIPO)的应用效果,并对其在剂量分布均匀性、靶区覆盖充分性以及危及器官保护有效性方面的表现进行评估。 方法 纳入2024年1月至2024年6月西南医科大学附属医院肿瘤科收治的45例宫颈癌患者,分别采用GO、HIPO及IPSA优化方法,为每位患者制定1例单次处方剂量为700 cGy的后装近距离放疗计划,形成GO组、IPSA组和HIPO组。评估分析高危临床靶区(high-risk clinical target volume, HRCTV)的D98、V200、V150和适形度指数,危及器官的D2cc、D1cc、D0.1cc等关键参数。 结果 IPSA组HRCTV D98高于HIPO组,差异有统计学意义(P < 0.001);HIPO组HRCTV V150高于IPSA组,差异有统计学意义(P < 0.05);HIPO组HRCTV CI高于其余2组,差异有统计学意义(P < 0.05)。GO组膀胱D2cc和D1cc均高于其余2组,差异有统计学意义(P < 0.05);GO组直肠D2cc高于HIPO组,差异有统计学意义(P < 0.05);其余危及器官剂量接近,差异未见统计学意义(P > 0.05)。3组计划制作时间差异显著(P < 0.001),其中GO组最长、IPSA组最短、HIPO组居中。 结论 HIPO算法在靶区剂量优化和危及器官剂量控制方面展现出显著优势,推荐作为宫颈癌后装近距离治疗的首选优化策略。
Objective To evaluate the performance of the Graphical Optimization (GO), Inverse Planning Simulated Annealing (IPSA), and Hybrid Inverse Planning Optimization (HIPO) algorithms concerning dose distribution uniformity, target coverage adequacy, and protection of organs at risk in cervical cancer brachytherapy. Methods Forty-five patients with cervical cancer admitted to the Department of Oncology of the Affiliated Hospital of Southwest Medical University from January 2024 to June 2024 were included, and one case of posterior-mounted brachytherapy with a single prescribed dose of 700 cGy was planned for each patient using the GO, HIPO and IPSA optimization methods to form the GO,IPSA and HIPO groups respectively. Evaluation and analysis of key parameters such as D98, V200, V150 and fitness index in high-risk clinical target volume (HRCTV) and D2cc, D1cc, D0.1cc in organ at risk. Results The HRCTV D98 in the IPSA group exceeded that of the HIPO group, exhibiting a statistically significant difference (P < 0.001). Conversely, the HRCTV V150 in the HIPO group surpassed the IPSA group, also showing a statistically significant difference (P < 0.05). The conformity index for the HRCTV in the HIPO group was higher than that in the other groups, with a statistically significant difference (P < 0.05). Regarding bladder doses, the GO group exhibited higher D2cc and D1cc values compared to the IPSA and HIPO groups, which was statistically significant (P < 0.05). Similarly, the GO group's rectal D2cc was significantly higher than that of the HIPO group (P < 0.05). Doses to other at-risk organs were comparable, with no statistically significant differences. Treatment plan production time varied significantly (P < 0.001), with the GO group requiring the most time, the IPSA group the least, and the HIPO group falling between the two. Conclusion The HIPO algorithm showed significant benefits in optimizing target dose and controlling doses to organs at risk, making it the recommended optimization strategy for cervical cancer brachytherapy.
| [1] |
|
| [2] |
|
| [3] |
李明秀, 许振, 石洪堂, |
| [4] |
韦蒙专, 陈绍俊, 黄海欣. 中晚期宫颈癌综合治疗模式的研究现状和进展[J]. 中国肿瘤, 2019, 28(6): 456-460. |
| [5] |
张嘉曦, 王芸芸, 张萌, |
| [6] |
|
| [7] |
中华医学会放射肿瘤治疗分会近距离治疗学组,中国医师协会放射肿瘤分会妇科肿瘤学组,中国抗癌协会近距离治疗专委会. 宫颈癌近距离腔内放疗二维治疗技术规范中国专家共识[J]. 中华放射肿瘤学杂志,2020,29(9):718-720. |
| [8] |
谭华艳, 卢敏, 邓烨, |
| [9] |
金鸽, 李魁秀, 郭云峰, |
| [10] |
|
| [11] |
|
| [12] |
杨文翠, 赵林, 赵凤菊, |
| [13] |
|
| [14] |
|
| [15] |
何赟, 李宇星, 王亚利, |
| [16] |
刘小龙, 庞皓文, 杨波. 基于等效均匀剂量的优化方法在宫颈癌调强放疗中的应用[J]. 西南医科大学学报, 2019, 42(2): 174-177. |
| [17] |
刘小龙, 庞皓文, 徐玮. 宫颈癌放疗中股骨头的剂量研究[J]. 西南医科大学学报, 2019, 42(1): 62-65. |
| [18] |
何赟, 李毅, 王亚利, |
| [19] |
孙澄澄, 秦云霞, 陈莉莉, |
| [20] |
李世婷, 陈绍俊. 中晚期宫颈癌近距离放疗技术的研究进展[J]. 癌症进展, 2023, 21(7): 711-713, 71. |
| [21] |
张露, 龚文, 谭榜宪. 宫颈癌根治性放疗方案的优化研究进展[J]. 肿瘤预防与治疗, 2018, 31(5): 358-363. |
| [22] |
李磊, 杨波. 施源器顶端重建偏差对宫颈癌三维腔内后装治疗的剂量学影响[J]. 西南医科大学学报, 2021, 44(2): 138-143. |
| [23] |
晏川钧, 王先良, 温爱萍, |
| [24] |
凌宝珍, 陈利, 张俊, |
| [25] |
薛涛, 孙云川, 刘光波, |
| [26] |
|
| [27] |
凌宝珍, 陈利, 张俊, |
| [28] |
张坤, 杨健, 牛书雷, |
| [29] |
陈开强, 游鸿强, 李奇欣, |
四川省医疗卫生与健康促进协会科研项目(KY2022SJ0377)
西南医科大学科技项目资助(2024ZKY023)
/
| 〈 |
|
〉 |